Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc by Poveda, Eva & Soriano, Vincent
© 2010 Poveda and Soriano, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
HIV/AIDS - Research and Palliative Care 2010:2 51–58
HIV/AIDS - Research and Palliative Care
51
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Optimizing management of treatment-naïve  
and treatment-experienced HIV+ patients:  
the role of maraviroc
Eva Poveda 
Vincent Soriano
Department of Infectious Diseases, 
Hospital Carlos III, Madrid, Spain
Correspondence:   Vincent Soriano
Department of Infectious Diseases, 
Hospital Carlos III, Calle Sinesio Delgado, 
10, Madrid 28029, Spain
Tel +34 91 453 25 00
Fax +34 91 7336614
Email vsoriano@dragonet.es
Abstract: Maraviroc is the first CCR5 antagonist approved for the treatment of HIV-1 infection. 
It specifically inhibits the replication of R5 viruses by blocking viral entry. HIV-1 tropism can be 
estimated accurately and predict viral response to maraviroc. Genotypic tools are increasingly 
replacing phenotypic assays in most places. The favorable pharmacokinetic properties and the 
good safety profile of maraviroc may support an earlier use of the drug in HIV-1 infection, as 
well as favor its consideration as part of switch strategies in patients under suppressive antiret-
roviral regimens containing less-well-tolerated drugs. Moreover, a particular immune benefit of 
maraviroc might encourage its use as part of intensification strategies in HIV-infected patients 
with impaired CD4 gains despite prolonged suppression of HIV replication with antiretroviral 
therapy. However, the long-term consequences of using maraviroc must be carefully checked, 
given its particular mechanism of action, blocking a physiologic cell receptor.
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Introduction
Although most HIV+ patients respond well to current antiretroviral regimens, a subset 
show treatment failure generally due to selection of drug resistance. For this reason, 
new therapeutic options for HIV+ patients continue to be needed. The development 
and approval of new antiretroviral drugs targeting different steps of the HIV replication 
cycle is one of the best ways to ensure this goal. These new drugs are active against 
HIV variants resistant to former compounds and generally exhibit better safety profiles. 
An attractive step in the HIV replication cycle to be targeted is viral entry.1,2 The 
fusion inhibitor enfuvirtide3 and the CCR5 antagonist maraviroc4 (Celsentri® [UK], 
Selzentry® [US]; Pfizer) are so far the only entry inhibitors approved for clinical use. 
Maraviroc is the first CCR5 antagonist and the unique oral HIV entry inhibitor. It was 
approved by the US Food and Drug Administration on June 2007 for the treatment 
of antiretroviral-experienced patients failing prior regimens. Maraviroc exclusively 
inhibits the replication of R5-tropic HIV variants by an allosteric mechanism after 
binding to the transmembrane CCR5 co-receptor cavity. This review goes over the main 
features of maraviroc, in an attempt to define its optimal use in clinical practice.
Mechanism of action of CCR5 antagonists
CCR5 antagonists are the newest agents that have entered the HIV armamentarium 
and the second class of entry inhibitors to gain regulatory approval. During the 
HIV entry process, the CD4-gp120 interaction induces conformational changes in 
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allows the CD4-gp120 complex to interact with a chemokine 
co-receptor, typically CCR5 or CXCR4. The CD4-gp120 
complex binds to either co-receptor through interactions with 
the V3 region of gp120, though other HIV gp120 regions 
such as V1/V2, C4 and the bridging sheet are also involved.5 
The use of CCR5 or CXCR4 co-receptors by HIV-1 is mainly 
determined by the amino acid sequence of the V3 region of 
gp120.6,7 Accordingly, HIV isolates are classified as either 
R5-tropic, X4-tropic, or as dual/mixed tropic, depending 
on their co-receptor use.8 The term dual/mixed refers to 
isolates that may contain true dual tropic viruses (particles 
that can use either or both chemokine co-receptors) or 
mixtures of viruses that exclusively use CCR5 and others 
that use CXCR4, thus giving the virus population a dual 
tropic character due to the mixed tropism of the individual 
viral variants.
Maraviroc is an allosteric inhibitor of the CCR5 
chemokine co-receptor, orally bioavailable with potent in 
vitro activity (IC90 ∼2 nM). Maraviroc binds to the trans-
membrane co-receptor cavity, within the 2, 3, 6 and 7 helix.9,10 
Following binding, CCR5 coreceptor conformational changes 
occur, especially in the ECL2 region, which ultimately mean 
that maraviroc can no longer interact with the V3 crown of 
the HIV envelope (Figure 1).
HIV tropism testing in the clinic
CCR5 antagonists do not display activity against CXCR4-
using HIV variants. Consequently, the presence of detectable 
X4 or R5/X4 dual-tropic viruses has been associated with 
therapeutic failure using maraviroc.11–13 Therefore, assess-
ment of HIV-1 tropism is required before recommending 
treatment with CCR5 antagonists. Several assays have been 
  developed to determine HIV tropism in clinical samples.14,15 
The Trofile® phenotypic assay (Monogram Biosciences, 
South San Francisco, CA), which is based on the recombinant 
virus technology,16 has been extensively utilized to provide 
tropism information in clinical trials, showing good correla-
tion with virological outcomes, and accordingly it has been 
the most widely used to date.15–17
The Trofile® assay identifies X4 strains with a sensitivity 
of 10% when using clonal mixtures, but does not differentiate 
between dually tropic viruses and mixtures of X4 and 
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R5 strains, reporting results as “dually or mixed” (D/M) 
virus.16 Monogram Biosciences has developed an enhanced 
sensitivity tropism assay (ESTA), which is 10- to 100-fold 
more sensitive for detecting X4 minor populations when 
using clonal mixtures.17 ESTA has been available since June 
2008 and has replaced the original Trofile® assay used in the 
pivotal clinical trials.
Although phenotypic assays such as Trofile® are consid-
ered reliable for assessing HIV tropism, they remain far from 
perfect as diagnostic tests for clinical purposes. They are labor 
intensive, expensive and require special laboratory facilities 
and expertize. They are not widely available, and in the case 
of Trofile® specimens must be shipped to the reference labora-
tory in the United States. Moreover, up to 15% of specimens 
are non-reportable even when testing samples with plasma 
HIV-RNA  1000 copies/mL. In recent years, efforts have 
been made to explore alternative testing approaches, mainly 
using genotypic predictors of viral tropism, as a guide to the 
use of maraviroc in clinical practice.
The reliability of genotypic tools to determine HIV 
  tropism in clinical samples compared with phenotypic assays 
has been examined in multiple studies, mainly conducted 
in Europe and Canada. Some of these comparisons showed 
relatively poor concordances, mainly due to low sensitivity 
(45%) in detecting X4 variants by genotypic algorithms;18 
however, more recent studies have demonstrated improved 
sensitivity when using certain genotypic tools and/or using 
phenotypic assays other than Trofile® as the reference 
“gold standard”.19–22 Different strategies to improve the 
  sensitivity of genotypic methods to detect X4 variants 
have been examined, including simple modifications in the 
  interpretation algorithms,23 or adding structural/biochemical 
properties of the V3 loop and clinical parameters such as 
CD4 and CD8 counts, and plasma viremia in the final report 
interpretation.24 Finally, another approach has combined the 
results given by different genotypic algorithms to produce a 
“pooled” X4 sensitive tropism prediction.25
The validation of genotypic tropism prediction methods, 
however, do not require perfect concordance with the Trofile® 
(or ESTA) assay, but rather evidence of a similar ability to 
correctly identify patients who will benefit from the use of 
maraviroc. In this context, recent studies have shown that 
the use of genotypic tropism prediction tools, based on 
V3 sequence data, have an ability similar to that of Trofile® 
to predict virological response to maraviroc and therefore 
can reliably guide clinical practice.26,27
The pyrosequencing technology may enable the 
  composition of viral quasispecies to be explored more 
deeply.28,29 It may provide a unique opportunity to enhance 
the sensitivity for identification of elusive minority 
  variants, including minimally present X4 viruses.30 
Ultradeep sequencing, however, is a sophisticated and 
expensive method, available in only a few research facilities. 
Moreover, the analysis of large amount of sequencing data 
generated for each sample remains quite challenging. Addi-
tionally, the interpretation of results is related to the optimal 
sensitivity threshold for X4 variants that may be clinically 
relevant. Preliminary data suggest that the proportion of 
X4 viruses beyond 5% (between 1% and 10%) may have a 
clinical impact, but not below this threshold, and therefore 
deeper exploration may not be needed in terms of clinical 
  application in routine diagnostic settings.
The potential for using maraviroc without knowing the 
result of a preceding tropism assay is also under debate. This 
approach could be of especial interest in antiretroviral-naïve 
patients with good CD4 counts in whom R5-tropic variants 
are predominant (74%–82%),31 or in subjects infected with 
HIV-1 subtypes with a low propensity for CXCR4 use, such 
as clade C.32
Efficacy and safety of maraviroc  
in clinical trials
Antiretroviral-naïve patients
The in vivo antiviral activity of maraviroc was initially 
described in a monotherapy study which compared several 
once-daily (QD) and twice-daily (BID) doses of the drug 
(25, 50, 100, 150, 300 mg) vs placebo over 10 days in HIV-
infected drug-naïve volunteers infected with R5-tropic 
viruses. Reductions in plasma HIV-RNA  1 log copies/mL 
were observed with all doses of 100 mg or greater.33
The MERIT trial evaluated the safety and efficacy 
of maraviroc (300 mg BID) vs efavirenz (600 mg QD), 
each in combination with zidovudine and lamivudine, in 
drug-naïve HIV-1 patients. The trial failed to demonstrate 
non-inferiority of either QD or BID maraviroc arms 
  compared to efavirenz using the attainment of plasma 
HIV-RNA  50 copies/mL at week 48 as the primary 
  endpoint.34 However, the non-inferiority was demonstrated 
for viral load suppression 400 HIV-RNA copies/mL. Subse-
quently, the MERIT trial was analyzed in detail to understand 
the virological correlates of treatment failure. In 13 patients 
receiving maraviroc (3.8%) a switch in viral tropism was 
observed from R5 to D/M between the screening and base-
line. In this subset of patients a reduced response to mara-
viroc compared to efavirenz was observed (54.6% vs 7.1% 
achieved 50 HIV-RNA copies/mL, respectively), while HIV/AIDS - Research and Palliative Care 2010:2 54
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for patients harboring R5 viruses, similar responses were 
observed between maraviroc and efavirenz groups (69.3% 
vs 68%, respectively) (Figure 2).35 Therefore, the presence 
of X4-variants within the quasispecies population at a rate 
just below the sensitivity threshold of the old Trofile® assay 
at baseline seemed to be an important predictor of failure on 
maraviroc in drug-naïve patients.
Consistent with this hypothesis, a re-analysis of the 
MERIT trial using ESTA reclassified as D/M nearly 15% 
of viruses from samples originally scored as having R5 by 
Trofile®. Following this new assignment, the proportion of 
patients achieving 50 HIV-RNA copies/mL at 48 weeks 
was the same (68%) in both maraviroc and efavirenz 
arms.36
More recently, the 96-week results of the MERIT trial 
were reported only for the subset of patients with baseline 
R5 using ESTA, and maraviroc remained non-inferior to 
efavirenz in terms of plasma HIV-RNA suppression below 
50 copies/mL (59% vs 62%, respectively); however, more 
patients discontinued efavirenz due to side effects while more 
failed virologically in the maraviroc arm.37
Since the proportion of patients harboring R5 variants in 
this drug-naïve population was 80%,36 the use of maraviroc 
as first-line therapy, especially in patients presenting with 
non-advanced immune deficiency, may be considered as 
an attractive option. In contrast, in advanced stages of HIV 
infection approximately half of the patients may harbor X4 
viruses as a dominant or just significant population.13
Antiretroviral-experienced patients
In the MOTIVATE 1 (conducted in the US and Canada) 
and MOTIVATE 2 (in Europe, Australia and the US) trials 
(Maraviroc plus Optimized Background Therapy in Viremic, 
ART-Experienced Patients), triple-class-resistant patients 
harboring R5-tropic virus at baseline were randomized to 
receive maraviroc 150 or 300 mg QD or BID or placebo, 
each combined with an optimized background regimen 
(OBR). In these double-blind, placebo-controlled studies, 
maraviroc plus an OBR demonstrated significantly greater 
  virological and immunological efficacy and similar safety 
profile compared with an OBR alone during 48 weeks. 
Nearly twice the percentage of patients on maraviroc BID 
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Figure 2 Efficacy of maraviroc in MOTIVATE and MERIT trials: 48-week results.
*Non-inferiority margin in –10%.
Abbreviations: OBR, optimized background regimen; ENF, enfuvirtide; MVC, maraviroc; EFV, efavirenz; ZDV, zidovudine.HIV/AIDS - Research and Palliative Care 2010:2 55
Maraviroc for HIV+ patients Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
plus OBR vs placebo plus OBR achieved the primary end-
point of plasma HIV-RNA  50 copies/mL compared with 
those receiving an OBR alone (45% vs 16%, respectively)38 
(Figure 2).
Maraviroc demonstrated a better virologic efficacy in 
treatment-experienced subjects when combined with 1 
active agent in the OBR. Overall the MOTIVATE trials 
  demonstrated the beneficial effect of combining both 
entry inhibitors maraviroc and enfuvirtide. The proportion 
of patients that achieved HIV-RNA  50 copies/mL was 
  substantially higher in patients who received enfuvirtide 
for the first time along with maraviroc than those who 
received enfuvirtide plus OBR, or those who received an 
OBR alone (61% vs 27% vs16 %) (Figure 2). Similar data 
were obtained in patients who received maraviroc along 
with a protease inhibitor (PI) for the first-time and lack-
ing PI-resistant mutations. Altogether these data point out 
the importance of including additional fully active agents 
when using maraviroc in heavily antiretroviral-experienced 
patients.38,39
The A4001029 study compared the activity of maraviroc vs 
placebo in treatment-experienced individuals with dual/mixed 
(D/M) or X4 viruses, who also received an OBR.40 This 
study showed no significant differences in plasma HIV-RNA 
outcomes in the maraviroc group compared to subjects who 
received placebo, highlighting the limited antiviral activity of 
maraviroc when confronting CXCR4-tropic viruses.
Recently Valdez et al41 showed that a weighted optimized 
background treatment susceptibility score, rather than low-
level X4 viruses at baseline (as defined as a change in Trofile® 
test result from R5 at screening to DM at baseline), was the 
strongest predictor of virological response at 48 weeks in the 
MOTIVATE trials. This finding highlights the contribution to 
virus suppression of other antiretroviral drugs, such as most 
nucleoside analogues or PIs, for which partial activity may 
be recognized when confronting viruses with only a few drug 
resistance mutations. It is the activity of the accompanying 
drugs that may enable maraviroc to benefit patients with a 
low proportion of X4 variants.
In this regard, a re-analysis of the maraviroc A4001029 
study, in which all enrolled patients had baseline evidence of 
X4 or D/M viruses by Trofile®, demonstrated by ultradeep 
sequencing that there is an inverse relationship between the 
proportion of plasma variants and the extent of virological 
responses to maraviroc.42 Overall, patients with a low preva-
lence of X4 variants (10%) showed a substantial viral load 
decline (-2.6 log HIV-RNA copies/mL at week 8), regard-
less of the result provided by Trofile®. If these results are 
confirmed, patients with 10% X4 variants might benefit 
from maraviroc therapy.
Based on these findings, it may be proposed that attempts 
at categorically excluding presence of X4 strains at very 
low frequency within the viral population may lead to the 
unnecessary exclusion of a therapeutic option that could still 
provide at least partial activity.
Maraviroc has demonstrated an excellent safety profile 
in clinical trials. Data from the MERIT trial showed that 
fewer patients discontinued maraviroc than efavirenz 
due to adverse events (4.2% vs 13.6%, respectively).34 
Moreover, lipid abnormalities occurred less frequently 
in patients taking maraviroc than efavirenz34 (Figure 3). 
Maraviroc can be given once a day (600 mg) as two pills,43 
causes minimal side effects and displays easily manageable 
drug interactions. No evidence of an increased incidence 
of malignancies was reported in the MOTIVATE trials. 
The favorable pharmacokinetic properties and the safety 
profile of maraviroc may support an earlier use of the drug 
in HIV-1 infection beyond the initial approval for antiretro-
viral-experienced patients.
Novel scenarios for maraviroc use
Simplification strategies
The long-term use of the most commonly prescribed 
antiretroviral drugs has been associated with a broad 
range of adverse events, including metabolic abnormalities,44 
increased  cardiovascular  risk,45,46  lipodistrophy,47 
hepatotoxicity,48 gastrointestinal disturbances49 and 
neuropsychiatric conditions.50 In contrast, maraviroc has 
demonstrated an excellent safety profile in clinical trials.34 
Maraviroc has also demonstrated a favorable pharmacokinetic 
profile when given once a day (600 mg) as two pills,42 
displaying easily manageable drug interactions. Its 
convenience and safety profiles may further support 
consideration of maraviroc as part of switch strategies in 
patients having suppressed HIV replication under regimens 
that are less well tolerated.
Immunological non-responders
In the MOTIVATE trials, a greater mean CD4 gain was 
observed in patients on maraviroc who experienced 
  virological failure compared to the placebo arm (mean 
[95% confidence interval (CI)]: +64 [47 to 82], +74 [56 to 
92] and +24 [10 to 40] cells/mm3, respectively).38,39 Based 
on this observation, treatment with maraviroc might provide 
an immunological benefit beyond its direct antiviral activity. 
This phenomenon has already been reported in HIV patients HIV/AIDS - Research and Palliative Care 2010:2 56
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failing the fusion inhibitor enfuvirtide;50–53 however, the 
underlying mechanisms are still unknown. The particular 
immune benefit provided by maraviroc therapy may support 
its use as part of intensification strategies for the subset of 
HIV+ individuals with low CD4 counts showing an impaired 
CD4 gain despite prolonged suppression of HIV replication 
with highly active antiretroviral therapy (HAART). Although 
preliminary results have so far being modest in this specific 
situation,54,55 further studies including larger number of 
patients and longer follow-up are warranted.
In HIV patients with undetectable viremia, determination 
of viral tropism in plasma is not feasible. Two alternative strate-
gies may be proposed in this situation. Firstly, viral tropism 
should be checked in stored plasma specimens collected before 
initiating HAART. Secondly, viral tropism should be assessed 
in current proviral DNA. Emerging information from studies 
examining the dynamics of viral tropism during prolonged 
HIV suppression under HAART and about the extent of cor-
relation between plasma and cell compartments support any of 
these approaches.56,57 Shifts in viral tropism under prolonged 
suppressive HAART seem to be very rare and correlation 
between plasma RNA and proviral DNA is good, although X4 
variants can be recognized more often in proviral DNA than 
in plasma. As a result, maraviroc might be confidently used 
as part of simplification or intensification strategies as long 
as viral tropism excluded X4 variants in retrospective plasma 
specimens, or following testing of current proviral DNA.
Conclusions
Maraviroc is the first CCR5 antagonist approved for the 
treatment of HIV-1 infection, which exclusively inhibits the 
replication of R5 viruses. HIV-1 tropism can accurately be 
estimated and predict viral response to maraviroc. Genotypic 
tools are increasingly replacing the initial phenotypic assays. 
The favorable pharmacokinetic properties and the good 
safety profile of maraviroc may support an earlier use of the 
drug in HIV-1 infection, as well as favor its consideration 
as part of switch strategies in patients under suppressive 
HAART with less-well-tolerated drugs. However, long-
term adverse events using this drug for long periods must 
be carefully checked, given the particular mechanism of 
action of maraviroc (blocking a physiologic cell receptor). 
A particular immune benefit of maraviroc might encourage 
the use of the drug as part of intensification strategies in 
HIV+ patients with impaired CD4 gains despite prolonged 
suppression of HIV replication under HAART. Finally, the 
performance of maraviroc in resource-limited settings must 
be examined, as the majority of persons infected with HIV 
live in such settings.
Acknowledgments
This work was funded in part by grants from Fundación 
Investigación y Educación en SIDA (IES), Red de Investig-
ación en SIDA (RIS, ISCIII-RETIC-RD06), and Fondo de 
Investigación Sanitaria (CP08/00214).
Total cholesterol
≥200 mg/dL
Triglycerides
≥200 mg/dL
LDL cholesterol
≥130 mg/dL
31%
22%
5%
14%
11%
8%
P
a
t
i
e
n
t
s
 
(
%
)
Efavirenz + CBV
Maraviroc + CBV
Figure 3 Lipid profile in the MERIT trial.HIV/AIDS - Research and Palliative Care 2010:2 57
Maraviroc for HIV+ patients Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Disclosures
The authors disclose no conflicts of interest.
References
  1.  Briz V , Poveda E, Soriano V . HIV entry inhibitors: mechanisms of action 
and resistance pathways. J Antimicrob Chemother. 2006;57:619–627.
  2.  Esté J, Telenti A. HIV entry inhibitors. Lancet. 2007;370:81–88.
  3.  Roberston D. US FDA approves new class of HIV therapeutics. Nat 
Biotechnol. 2003;21:470–471.
  4.  Anonymous. FDA approves maraviroc tablets. AIDS Patient Care STDs. 
2007;21:702.
  5.  Comier E, Dragic T. The crown and stem of the V3 loop play distinct 
roles in HIV type 1 envelope glycoprotein interactions with the CCR5 
coreceptor. J Virol. 2002;76:8953–8957.
  6.  Chan S, Speck R, Power C, et al. V3 recombinants indicate a central 
role for CCR5 as coreceptor in tissue infection by HIV type 1. J Virol. 
1999;73:2350–2358.
  7.  Jensen M, Van’t Wout A. Predicting HIV-1 coreceptor usage with 
sequence analysis. AIDS Rev. 2003;19:145–149.
  8.  Berger E, Doms R, Fenyö E, Korber BT, Littman DR, Moore JP, et al. 
A new classification for HIV-1. Nature. 1998;391:240.
  9.  Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. 
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective 
small-molecule inhibitor of chemokine receptor CCR5 with broad-
spectrum anti-HIV type 1 activity. Antimicrob Agents Chemother. 
2005;49:4721–4732.
  10.  Castonguay L, Wengg Y, Adolfsen W, Di Salvo, Kilburn R,   
Caldwell C, et al. Binding of 2-aryl-4(piperidin-1yl)butanmines 
and 1, 3, 4-trisubstitued pyrrolidines to human CCR5: a molecular 
  modelling-guide mutagenesis study of the binding pocket. Biochemistry. 
2003;42:1544–1550.
11.  Saag M, Goodrich J, Fatkenheuer G, Clotet B, Clumeck N, Sullivan J, 
et al. A double-blind, placebo-controlled trial of maraviroc in treatment-
experienced patients infected with non-R5 HIV-1. J Infect Dis. 
2009;199:1638–1647.
12.  Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman A, 
Lampiris H, et al. Subgroup analyses of maraviroc in previously treated 
R5 HIV-1 infection. N Engl J Med. 2008;359:1442–1455.
13.  Vandekerckhove L, Verhofstede C, Vogelaers D. Maraviroc:  spectives 
for use in antiretroviral-naïve HIV-1-infected patients. J Antimicrob 
Chemother. 2009;63:1087–1096.
14.  Poveda E, Briz V , Quinones-Mateu M, Soriano V . HIV tropism: diag-
nostic tools and implications for disease progression and treatment with 
entry inhibitors. AIDS. 2006;20:1359–1367.
15.  Rose J, Rhea A, Weber J, Quiñones-Mateu M. Current tests to 
evaluate HIV-1 coreceptor tropism. Current Opin HIV AIDS. 2009;4: 
136–142.
16.  Whitcomb J, Huang W, Fransen S, Limoli K, Toma J, Wrin T, et al. 
Development and characterization of a novel single-cycle recombinant-
virus assay to determine HIV type 1 coreceptor tropism. Antimicrob 
Agents Chemother. 2007;51:566–575.
17.  Trinh L, Han D, Huang W, Wrin T, Larson J, Kiss L, et al. Technical 
validation of an enhanced sensitivity Trofile HIV coreceptor tropism 
assay for selecting patients for therapy with entry inhibitors targeting 
CCR5. Antivir Ther. 2008;13(Suppl 3):A128.
18.  Low A, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, et al. Current 
V3 genotyping algorithms are inadequate for predicting X4 co-receptor 
usage in clinical isolates. AIDS. 2007;21:F17–F24.
19.  Poveda E, Briz V , Roulet V , González MM, Faudon J, Skrabal K, et al. 
Correlation between a phenotypic assay and three bioinformatics tools 
for determining HIV coreceptor use. AIDS. 2007;21:1487–1490.
20.  Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, 
Sandres-Sauné K, et al. Correlation between genotypic predictions 
based on V3 sequences and phenotypic determination of HIV-1 tropism. 
AIDS. 2008;22:F11–F17.
21.  Garrido C, Roulet V, Chueca N, Poveda E, Aguilera A, Skrabal K, 
et al. Evaluation of eight different bioinformatics tools to predict 
viral tropism in different HIV-1 subtypes. J Clin Microbiol. 2008;61: 
694–698.
22.  de Mendoza C, Van Baelen K, Poveda E, Rondelez E, Zahonero N, 
Stuyer L, et al. Performance of a population-based HIV-1 tropism 
phenotypic assay and correlation with V3 genotypic prediction 
tools in recent HIV-1 seroconverters. J Acquir Immune Defic Syndr. 
2008;48:241–244.
23.  Poveda E, Seclén E, Gonzalez M, García F, Chueca N, Aguilera A, 
et al. Design and validation of new genotypic tools for easy and reliable 
estimation of HIV tropism before using CCR5 antagonists. J Antimicrob 
Chemother. 2009;63:1006–1010.
24.  Strang A, Cameron J, Booth C, Garcia-Diaz A, Geretti AM. Genotypic 
prediction of viral co-receptor tropism: correlation with enhanced 
Trofile. 7th European HIV Drug Resistance Workshop. Stockholm, 
Sweden. March 25–27 2009 [abstract 80].
25.  Chueca N, Martin L, Alvarez M, Peña A, Guillot V , Garcia-Casas V , 
et al. A combination of bioinformatics tools can be accurately used 
for the screening of coreceptor usage in clinical samples. Antivir Ther. 
2008;13(Suppl 3):A106.
26.  Harrigan PR, McGovern R, Dong W, Thielen A, Jensen M, Mo T, 
et al. Screening for HIV tropism using population-based V3 geno-
typic analysis: a retrospective virological outcome analysis using 
stored plasma screening samples from MOTIVATE-1. Antivir Ther. 
2009;14(Suppl):A17.
27.  Obermeier M, Carganico A, Berg T, Hintsche B, Koppe S, Moll A, 
et al. The Berlin Maraviroc cohort – influence of genotypic tropism 
testing results on therapeutic outcomes. In: 7th European HIV Drug 
Resistance Workshop. Stockholm, Sweden. March 25–27 2009 
[abstract 79].
28.  Tsibris A, Korber B, Arnaout R, Russ C, Lo C, Leitner T, et al. Quantita-
tive deep sequencing reveals dynamic HIV-1 escape and large popula-
tion shifts during CCR5 antagonist therapy in vivo. PLoS One. 2009;4:
e5683.
29.  Archer J, Braverman M, Taillon B, Desany B, James I, Harrigan PR, 
et al. Detection of low-frequency pre-therapy chemokine (CXC motif) 
receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. 
AIDS. 2009;23:1209–1218.
30.  Däumer M, Kaiser R, Klein R, Lengauer T, Thiele B, Thielen A. 
Inferring viral tropism from genotype with massively parallel sequenc-
ing: qualitative and quantitative analysis. [abstract]. Antivir Ther. 
2008;13(Suppl 3):A101.
31.  Brumme Z, Goodrich J, Mayer H, Brumme C, Henrick B, Wynhoven B, 
et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 
in a large population of antiretroviral-naive individuals. J Infect Dis. 
2005;192:466–474.
32.  Ping L, Nelson J, Hoffman I, Schock J, Lamers S, Goodman M, et al. 
Characterization of V3 sequence heterogeneity in subtype C HIV type 1 
isolates from Malawi: underrepresentation of X4 variants. J Virol. 
1999;73:6271–6281.
33.  Fatkenheuer G, Pozniak A, Johnson M, Johnson M, Plettenberg A, 
Staszewski S, et al. Efficacy of short-term monotherapy with maraviroc, 
a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 
2005;11:1170–1172.
34.  Saag M, Ive P, Heera J, Tawadrous M, DeJesus E, Clumeck N, et al. 
A multicenter, randomized, double-blind, comparative trial of a novel 
CCR5 antagonist, maraviroc vs efavirenz, both in combination with 
Combivir (zidovudine/lamivudine), for the treatment of antiretroviral 
naive patients infected with R5 HIV-1: week 48 results of the MERIT 
study. 4th IAS Conference on HIV pathogenesis, treatment and preven-
tion, Sydney, Australia, 2007. Abstract WESS104.
35.  Heera J, Saag M, Ive P, Whitcomb J, Lewis M, McFadyen L, et al. 
Virological correlates associated with treatment failure at week 48 in 
the phase 3 study of Maraviroc in treatment-naïve patients. 15th Confer-
ence on Retroviruses and Opportunistic Infections, Boston, MA, 2008. 
Abstract 40LB.HIV/AIDS - Research and Palliative Care 2010:2
HIV/AIDS - Research and Palliative Care
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/hivaids---research-and-palliative-care-journal
HIV/AIDS - Research and Palliative Care is an international, peer-
reviewed open-access journal focusing on advances in research in HIV , 
its clinical progression and management options including antiviral 
treatment, palliative care and public healthcare policies to control 
viral spread. The journal welcomes original research, basic science, 
clinical & epidemiological studies, reviews & evaluations, expert 
opinion & commentary, case reports & extended reports. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
58
Poveda and Soriano Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
36.  Saag M, Heera J, Goodrich J, DeJesus E, Clumeck N, Cooper D, 
et al. Reanalysis of the MERIT study with the enhanced Trofile Assay 
(MERIT-ES). 48th ICAAC Annual/IDSA 46th Annual Meeting;   
October 25–28, 2008; Washington, DC. Abstract H-1269.
37.  Nelson M; on behalf of the MERIT study team. 96-week results of the 
MERIT trial. International AIDS Conference. Cape Town, July 2009 
[abstract MOPEBO4O].
38.  Gulick R, Lalezari J, Goodrich J, Clumeck N, De Jesus E, Horban A, 
et al. Maraviroc for previously treated patients with R5 HIV-1 infection. 
N Engl J Med. 2008;359:1429–1441.
39.  Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, 
Lampiris H, et al. Subgroup analyses of maraviroc in previously treated 
R5 HIV-1 infection. N Engl J Med. 2008;359:1442–1455.
40.  Saag M, Goodrich J, Fatkenheuer G, Clotet B, Clumeck N, Sullivan J, 
et al. A double-blind, placebo-controlled trial of maraviroc in treatment-
experienced patients infected with non-R5 HIV-1. J Infect Dis. 
2009;199:1638–1647.
41.  Valdez H, Lewis M, Delogne C, Simpson P. Weighted OBT suscepti-
bility score (wOBTSS) is a stronger predictor of virologic response at 
48 weeks than baseline tropism result in MOTIVATE 1 and 2. Program 
and abstract of the 48th Annual ICAAC/IDSA 46th Annual Meeting; 
October 25–28, 2008; Washington, DC. Abstract H-1221.
42.  Swenson L, Dong W, Mo T, Woods C, Thielen A, Jensen M, et al. 
Quantification of HIV Tropism by “deep” sequencing shows a broad 
distribution of prevalence of X4 variants in clinical samples that is 
associated with virological outcome. 16th Conference on Retroviruses 
and Opportunistic Infections; 8–11 February 2009, Montreal, Canada. 
Abstract 680.
43.  Abel S, Back D, Vourvahis M. Maraviroc: pharmacokinetics and drug 
interactions. Antivir Ther. 2009;14:607–618.
44.  Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and 
highly active antiretroviral therapy. Curr Diab Rep. 2009;9:37–42.
45.  D:A:D Study Group, Sabin C, Worm S, Weber R, Reiss P, El-Sadr W, 
et al. Use of nucleoside reverse transcriptase inhibitors and risk of 
myocardial infarction in HIV-infected patients enrolled in the D:A:D 
study: a multicohort collaboration. Lancet. 2008;371:1417–1426.
46.  Lundgren J, Reiss P, Worm S, Weber R, El-Sadr W, De Wit S, et al. 
Risk of myocardial infarction with exposure to specific ARV from the 
PI, NNRTI, and NRTI drug classes: the D:A:D study. 16th Conference 
on Retroviruses and Opportunistic Infections; 8–11 February 2009, 
Montreal, Canada. Abstract 44LB.
47.  Giralt M, Domingo P, Gallart J, Rodriguez de la Concepción ML, 
Alegre M, Domingo J, et al. HIV-1 infection alters gene expression in 
adipose tissue, which contributes to HIV-1/HAART-associated lipodys-
trophy. Antivir Ther. 2006;11:729–740.
48.  Soriano V , Puoti M, Garcia-Gasco P, Rockstroh J, Benhamou Y, Barreiro P, 
et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1–13.
49.  Hill A, Balkin A. Risk factors for gastrointestinal adverse events in HIV 
treated and untreated patients. AIDS Rev. 2009;11:30–38.
50.  Poveda E, Rodés B, Labernardière JL, Benito J, Toro C, González-Lahoz J, 
et al. Evolution of genotypic and phenotypic resistance to enfuvirtide in 
HIV-infected patients experiencing prolonged virologic failure. J Med 
Virol. 2004;74:21–28.
51.  Wei X, Decker J, Liu H, Zhang Z, Arani R, Kilby J, et al. Emergence 
of resistant HIV-1 in patients receiving fusion inhibitor (T-20) 
  monotherapy. Antimicrob Agents Chemother. 2002;46:1896–1905.
52.  Aquaro S, D’Arrigo R, Svicher V, Di Perri G, Lo Caputo S, 
Visco-Comandini U, et al. Specific mutations in HIV-1 gp41 are associ-
ated with immunological success in HIV-1 infected patients receiving 
enfuvirtide treatment. J Antimicrob Chemother. 2006;58:714–722.
53.  Poveda E, Briz V , Soriano V . Enfuvirtide, the first fusion inhibitor to 
treat HIV infection. AIDS Rev. 2005;7:139–147.
54.  Lanzafame M, Lattuada E, Vento S. Maraviroc and CD4+ cell count 
recovery in patients with virologic suppression and blunted CD4+ cell 
response. AIDS. 2009;27:869.
55.  Stepanyuk O, Chiang T, Dever L, Paez S, Smith S, Perez G, et al. Impact 
of adding maraviroc to antiretroviral regimens in patients with full viral 
suppression but impaired CD4 recovery. AIDS. 2009;23:1911–1913.
56.  Seclén E, González MM, Soriano V, Poveda E. Dynamics of viral 
tropism in HIV-infected patients under prolonged HIV-RNA suppres-
sion under HAART. 7th European HIV Drug Resistance Workshop. 
Stockholm 25–27 March 2009. Abstract 26.
57.  Waters L, Scourfield A, Marcano M, Gazzard B, Nelson M. The 
  evolution of co-receptor tropism in patients interrupting suppressive 
HAART. 16th Conference on Retroviruses and Opportunistic Infections; 
8–11 February 2009, Montreal, Canada. Abstract 439a.